Stockscreener 앱 받기
33.43
0.59%
-0.20
시장 영업 전:
33.43
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Institutional scanner results for Xenon Pharmaceuticals Inc.Free Market Surge Signal for Swing Traders - Newser
Quantitative breakdown of Xenon Pharmaceuticals Inc. recent moveFree AI Trading Suggestions With Accuracy Focus - Newser
Xenon Pharma Q2 2025 Earnings Preview - MSN
Xenon Pharmaceuticals Inc. stock trendline breakdownHigh Yield Signals with Entry Timing - Newser
Momentum divergence signals in Xenon Pharmaceuticals Inc. chartFree Stock Portfolio Allocation Guidance - Newser
Is it too late to sell Xenon Pharmaceuticals Inc.Short Term Gain Strategy with AI Logic - Newser
Xenon Pharmaceuticals XENE 2025Q2 Earnings Preview Upside Potential on Innovative Product Launches - AInvest
Xenon Pharmaceuticals Inc expected to post a loss of 99 cents a shareEarnings Preview - TradingView
Fund Update: GEODE CAPITAL MANAGEMENT, LLC added 900,746 shares of XENON PHARMACEUTICALS ($XENE) to their portfolio - Quiver Quantitative
Will Xenon Pharmaceuticals Inc. continue its uptrendMonthly Trade Result and Signal Summary - Newser
Measuring Xenon Pharmaceuticals Inc.’s beta against major indicesFree Stable Entry High Return Opportunities - Newser
Xenon Pharmaceuticals Skyrockets 8.9%—What’s Fueling This Biotech Breakout? - AInvest
Xenon Pharmaceuticals to Announce Q2 2025 Financial Results - The Globe and Mail
Signal strength of Xenon Pharmaceuticals Inc. stock in tech scannersEntry Confirmation Using Short-Term Forecasting - Newser
Is Xenon Pharmaceuticals Inc. stock poised for growthFree Target Return Focused Trade Insights - Newser
Xenon Pharmaceuticals Announces Q2 2025 Financial Results and Business Update - AInvest
Why Xenon Pharmaceuticals’ Stock is Gaining Attention - TipRanks
Xenon Pharmaceuticals Inc. to Report Q2 2025 Financial Results and Business Update on August 11, 2025 - Quiver Quantitative
Xenon to Report Q2 2025 Financial Results on August 11, 2025 - GlobeNewswire
Xenon Pharmaceuticals Sets Q2 Earnings Date: Key Updates Expected on Epilepsy Drug Azetukalner - Stock Titan
Will a bounce in Xenon Pharmaceuticals Inc. offer an exitMulti-Year Signal Summary and Entry Timing - Newser
Identifying reversal signals in Xenon Pharmaceuticals Inc.Sector-Wise Stock Strength Trend Analysis - Newser
Why is Xenon Pharmaceuticals Inc. stock attracting strong analyst attentionUnlock market-leading stock analysis - Jammu Links News
Using economic indicators to assess Xenon Pharmaceuticals Inc. potentialFree Weekly Potential Breakout Stock List - Newser
What drives Xenon Pharmaceuticals Inc. stock priceGet professional guidance for market timing - Jammu Links News
Xenon Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayPortfolio Risk Distribution Analysis Tool - Newser
What are the latest earnings results for Xenon Pharmaceuticals Inc.Discover the fastest growing stocks today - Jammu Links News
When is Xenon Pharmaceuticals Inc. stock expected to show significant growthUnlock exclusive stock market insights - Jammu Links News
How does Xenon Pharmaceuticals Inc. compare to its industry peersFree Daily Trading Room Entry - Jammu Links News
What catalysts could drive Xenon Pharmaceuticals Inc. stock higher in 2025Capitalize on market trends before they peak - Jammu Links News
What is Xenon Pharmaceuticals Inc. company’s growth strategyRapid growth opportunities - Jammu Links News
Is Xenon Pharmaceuticals Inc. a good long term investmentBuild wealth with proven stock investing tactics - Jammu Links News
What’s the recovery path for long term holders of Xenon Pharmaceuticals Inc.Free Fundamental + Technical Hybrid Stock Tips - Newser
Xenon Pharmaceuticals Inc. Stock Analysis and ForecastCapitalize on market momentum for profits - Jammu Links News
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Federated Hermes Inc. - Defense World
Using data tools to time your Xenon Pharmaceuticals Inc. exitFree Oversold Recovery Opportunity Stocks - Newser
Is Xenon Pharmaceuticals Inc. still worth holding after the dipAI Trend Detection for Entry Timing - Newser
Is a relief rally coming for Xenon Pharmaceuticals Inc. holdersFree Accurate Technical Trend Reversal Picks - Newser
Is it the right time to buy Xenon Pharmaceuticals Inc. stockGain access to exclusive stock analysis - Jammu Links News
What is the dividend policy of Xenon Pharmaceuticals Inc. stockUnlock expert market analysis instantly - Jammu Links News
Is Xenon Pharmaceuticals Inc. stock overvalued or undervaluedFree Stock Market Knowledge Sharing - Jammu Links News
How volatile is Xenon Pharmaceuticals Inc. stock compared to the marketBreakneck growth rates - Jammu Links News
Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees - The Globe and Mail
Xenon Pharmaceuticals Inc. stock trend forecastSafe Investment Ideas with Growth Upside - Newser
Assetmark Inc. Has $669,000 Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Short Interest Update - Defense World
Visual analytics tools that track Xenon Pharmaceuticals Inc. performanceTechnical Screener for High Growth Stocks - Newser
Has Xenon Pharmaceuticals Inc. found a price floorRisk Managed Watchlist with Breakout Picks - Newser
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xenon Pharmaceuticals Expands Team: Grants $739K in Stock Options to 6 New Hires - Stock Titan
Envestnet Asset Management Inc. Sells 4,447 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Can you recover from losses in Xenon Pharmaceuticals Inc.Free Entry Zone Strategy for Consistent Profit - Newser
Why Xenon Pharmaceuticals Inc. stock attracts strong analyst attentionTrend Confirmation Scanner with Entry Focus - Newser
0.24%
3.39%
자본화:
|
볼륨(24시간):